2026 Poster Presentations
Poster Awards announced Wednesday at 10:15 am and Thursday at 1:00 pm
POSTER SESSION A: Monday (evening) - Wednesday (morning) Conference Section B
A01: Oligo, Peptide, VHH, and Conjugate Manufacturing Using Ajiphase and Corynex, Presented by Yohei Y., Ajinomoto Bio-Pharma Services
A02: Liquid State Intelligence: A Coalescence-Based Measurement Class for Antibody Developability and Formulation Screening, Presented by Jack H., Apoha Limited
A03: The Largest Overlooked Cost Driver in Viral Vector Production, Presented by Jørn H., ArcticZymes
A04: Case Studies with Planova™ FG1: Next-Generation Virus Removal Filters for Rapid Flux, Presented by Christine S., Asahi Kasei Bioprocess
A05: Engineering Precision with CHO Edge: A Framework for Producing Complex Multispecific and Difficult-to-Express Proteins, Presented by Sai G., Asimov, Inc.
A06: Bayesian Optimization–Driven Media Optimization Enables Stable and Enhanced Antibody Production in Perfusion Culture, Presented by Yukito K., Astellas Pharma, Inc.
A07: Beyond High Titers: Expanding Leap-In Transposase® as a Generalized Host Engineering Tool, Presented by Varsha S., ATUM
A08: A DNA Barcoding Platform for High-Throughput Cell Line Development: Screening Thousands of Clones Under Manufacturing-Relevant Conditions, Presented by Junneng W., Biolinco, Inc.
A09: Characterization of Novel Engineering Targets in hiPSCs to Resist Allogenic Immune Cell Rejection, Presented by Hui Z., Bluerock Therapeutics
A10: Enabling End-to-End Automated Exploration of Biotherapeutic Liquid Formulations, Presented by Dennis W., Boehringer Ingelheim Pharma GmbH & Co. KG
A11: High Recovery Continuous Affinity Capture and Polishing of AAV via Column-Free BioRMB™ Chromatography, Presented by Michael G., Chromatan, Inc.
A12: Early Detection of CHO Cell Line Instability from Population Shifts Using scRNA-seq, Presented by Kohei Y., Chugai Pharmaceutical Co., Ltd.
A13: Unlocking Flexibility in Viral Vector Manufacturing: High-Efficiency DNA Removal - Engineered to Fit Your Process, Presented by Melissa R., c-LEcta - A Kerry Company
A14: Advancing Cell Dissociation in Bioprocessing with CellTrypase: A Novel, High-Purity Trypsin-Like Enzyme for GMP Workflows, Presented by José V., c-LEcta - A Kerry Company
A15: Biophysical Characterization of Adeno-Associated Virus (AAV) Vectors Using Orthogonal Analytical Technologies, Presented by Dongliang Z., Frontage Laboratories
A16: Innovative Chemically Defined Medium Supports Intensified AAV and LV Production in HEK293 Cells, Presented by Sama G., FUJIFILM Biosciences
A17: Mitigating Cell Retention Filter Fouling for 2000L High-Density Perfusion Culture, Presented by Naomichi H., FUJIFILM Corporation
A18: AI-Engineered NovoBody™-Based Probe for “High Capacity, Low Drift” BLI Analysis of His-Tagged Proteins, Presented by Benjamin O., Gator Bio
A19: Digitalizing CMC Processes at Novartis, Presented by Hagen K., Genedata AG
A20: Challenges and Approaches of Low-Dose Intravenously Administered Early-Stage Molecules, Presented by Jordan J., Gilead Sciences
A21: Mitigating the Impact of Vendor Raw Material Changes on Process Performance, Presented by Cynthia L., Gilead Sciences
A22: Automation and Optimization of Cell Line Development Using Liquid Handling, Presented by Kavil P., Gilead Sciences
A23: Parallelizing Molecular Discovery and Early CMC: The PCC Prime Foundry Powered by AI-Driven Site-Specific Integration, Presented by Michael C., Great Bay Bio
A24: Accelerating Biologics Development with Platform Solutions, Presented by Nikolette M., KBI Biopharma
A25: MTM-Based PAT-Guided Lyophilization Cycle Development for mRNA-LNP Formulations, Presented by Jihye L., KBIO Osong Medical Innovation Foundation
A26: Analytical Method Lifecycle Management: A Framework for Robust and Compliant Analytical Methods, Presented by Elaine Y., Legend Biotech
A27: Next-Generation GS® Expression Vector for Therapeutic Protein Manufacturing Using CHO Cells, Presented by Malak A., Lonza Biologics
A28: Advancing the Discovery and Development of Biologics and Next-Generation Immunotherapies Through Innovative Expression and Screening Techniques, Presented by Nitin K., MaxCyte, Inc.
A29: Optimization Tools for VHH Single Domain Antibody Developability via High Throughput Characterization, Presented by Riley F., Merck & Co., Inc.
A30: In-Line Raman Spectroscopy for End-to-End TFF Process Monitoring, Presented by Alexander F., MilliporeSigma
A31: Tunable-Laser NIR for High Concentration Proteins: A Rapid and Transferrable Spectroscopic Approach to Biologics Characterization and Stability, Presented by Hannah F., Nirrin Technologies
A32: Identification and UV-MS Quantitation of Process Impurities and Degradants in Oligonucleotide Therapeutics, Presented by Uday V., Pace Life Sciences
A33: Process Intensification: From Unit Operation to Complete Process, Presented by Kyllan A., Pak Biosolutions
A34: Real World Use of Ultra Low Flow Mass Spectroscopy for Critical Respiration Measurements of Mammalian Cell Culture in Small Glass Bioreactors (3 L), Presented by Tim P., Process Insights
A35: From Scratch to Subcutaneous: De-Risking High-Concentration Formulation in Months, Presented by Richard P., ProJect Pharmaceutics GmbH
A36: Light as a Novel Process Lever: High Productivity CHO Manufacturing with Applications in Monoclonal Antibodies and Beyond, Presented by Alex N., Prolific Machines
A37: Risk-Based Approach to Process Characterization of the Lysis and Harvest Step of a Commercially Enabling AAV Program, Presented by Syeda B., Regeneron Pharmaceuticals
A38: ÄKTA Scale Studies on Multi-Product Resin Reuse (MRR), Presented by Nabin K., Regeneron Pharmaceuticals
A39: Closing the Loop: Native Waters™ Empower™ Connectivity for LabChip™ GX/GXII Touch™ Instruments, Presented by James W., Revvity
A40: CHOSOURCE™ Transposon Technology: Enhancing Speed, Stability and Productivity, Presented by Austin H., Revvity
A41: Methylcellulose Supports Suspension Cell Process Intensification, Presented by Joshua K., Roquette
A42: Continuous Downstream Process Orchestration in Pionic Platform, Presented by Lara S. & Luca S., Sartorius Stedim Biotech GmbH
A43: AI-Native Protein Characterization for Next-Generation Biotherapeutics, Presented by Andrew R., Stanford University
A44: Integrated Computational and Experimental Analysis Identifies Caffeamide Derivative EK8 as a Retinal Protective Through Targeting MMP-9 and Microglial Hyperactivation in AMD, Presented by Yu-Wen C., Taipei Medical University
A45: Integrated Computational and Experimental Analysis Identifies 3,4-Dihydroxybenzalacetone as a Photoreceptor-Protective Fungal Compound Against Blue Light-Induced Retinal Degeneration, Presented by George H., Taipei Medical University
A46: Turning Data into Decisions for mAb Development and Production, Presented by Darren B., Thermo Fisher Scientific
A47: Gibco ID Media Service - Rapid Identity Verification Testing for Bioprocessing Materials, Presented by Gobind S., Thermo Fisher Scientific
A48: Universal Rapid Clear® 24-Well Filter Plate (7mL); A 5-Minute Spin for Clarification Solution for all Molecule Types, Presented by Alberto E., Thomson Instrument Company
A49: Comparison of Thomson Optimum Growth® 7L Flasks vs Ambr® 250 Bioreactor Systems Using Stable CHO Cells, Presented by Jordan L., Thomson Instrument Company
A50: Downstream Process Intensification by 2-Chromatography Step Processes, Next-Gen. Resins, and Multi-Column Chromatography, Presented by Jennifer K., Tosoh Bioscience
A51: Expediting Biologics Production Through the Innovative sxRNA-Select Cell Line Development Platform, Presented by Suman S., University at Albany, State University of New York
A52: High Efficiency Protein A Affinity Columns for the LC-MS and 2D LC-MS Analysis of mAb and msAb, Presented by Nick P., Waters Corporation
A57: Enabling Regulatory Success for Oligonucleotide and RNA Therapeutics Through Strategic CMC Design, Presented by Jyotsna A., Jaipur National University (Virtual Poster)
POSTER SESSION B: Wednesday (afternoon) - Thursday Conference Section C
B01: Quantifying Aggregate Removal by Cation-Exchange Chromatography: A High-Aggregate Monoclonal Antibody Case Study, Presented by Leslie I., Alexion, AstraZeneca Rare Disease
B03: Assessment of Recombinant Cascade Reagent (rCR) Based Endotoxin Testing Across Bioprocess Matrices, Presented by Jes T., Alexion, AstraZeneca Rare Disease
B04: Liquid State Intelligence: A Coalescence-Based Measurement Class for Discovery, Formulation, and Bioprocessing, Presented by Vivek R., Apoha Limited
B05: Case Studies with Next-Generation Planova™ Virus Removal Filters: FG1 for Rapid Flux and S20N for Challenging Solutions, Presented by Sara G., Asahi Kasei Bioprocess
B06: PFAS-Free Future: Advanced Materials for Next-Gen Virus Filtration, Presented by Jennifer Z., Biogen
B07: GLP-1 Biosimilar Purification: Streamlined Workflow for High Purity, Presented by Sharon B., Bio-Rad Laboratories
B08: Two-in-One: Efficient Co-Spiked Viral Clearance Testing of a mAb Purified using a Weak AEX-HIC Resin, Presented by William R., Bio-Rad Laboratories
B09: Enhancing Purity of an Emtansine Biosimilar ADC Through Mixed-Mode Chromatography, Presented by Renee S., Bio-Rad Laboratories
B10: A Simple Strategy to Convert a Single Column Chromatography Process to a PCC Process, Presented by Kady O., Boston Institute of Biotechnology
B11: Supplemental Characterization of Viral Clearance Robustness Across the Viral Filtration Step, Presented by Emma K., Bristol Myers Squibb
B12: Characterizing Process Performance and Robustness in an End-to-End Cryopreserved Autologous CAR-T/TCR Workflow, Presented by Robert B., CARR Biosystems
B13: Cell Culture Process and Manufacturing Control Strategies to Mitigate Color Change in Antibody Drug Substance, Presented by Yasuharu S., Chugai Pharma Manufacturing Co., Ltd.
B14: CFD-Driven Quantification of Aeration-Agitation Stress to Bridge Scale-Up Gaps in CHO Bioreactors, Presented by Yuta H., Chugai Pharmaceutical Co., Ltd.
B15: Rational Bioprocess Optimization Through Integrated Spent Media Metabolomics and Genome-Scale Metabolic Modeling, Presented by Adi K., Clarity Biosystems Consulting
B16: Purity Matters: Multifunctional Roles of L-Arginine and L-Histidine in Bioprocessing and Formulation, Presented by Kritika B., Croda, Inc.
B17: Scalable Chromatography Platform Designed to Disrupt the Bioprocessing Industry, Presented by James L., Donaldson Company, Inc.
B18: Human Induced Pluripotent Stem Cell (hiPSC) Aggregate Expansion in Stirred-Tank Bioreactors Using the SciVario® Twin Bioprocess Controller, Presented by Hridesh B., Eppendorf North America
B19: Mitigating Trace Metal Variability in Chemically Defined Media for Consistent Bioprocess Performance, Presented by Catherine N., FUJIFILM Biosciences
B20: QbD-Driven Process Intensification Strategy for Commercial Manufacturing, Presented by Min-Jung K., GC Biopharma
B21: Next Era of Bioprocessing: Driving Innovation Through Digital CMC and AI, Presented by Jolyon T., Genedata, Inc.
B22: The Roche Global Preclinical AAV Vector Production Core: Integrated, Scalable AAV Production and Analytics to Accelerate Patient Access, Presented by Bin Z., Genentech, Inc.
B23: Recombinant Polyclonal Therapeutics: A Platform Approach to Infectious Disease Treatment, Presented by Yibing Y., GigaGen, Inc.
B24: Product Quality Attribute–Driven Selection of New CHO Cell Line During Late-Stage Development, Presented by Niki F., Gilead Sciences
B25: Modernizing a Legacy Cell Culture Platform for Robust and Rapid Early-Stage Development, Presented by Jin G., Gilead Sciences
B26: Iron-ing Out the Challenges in Commercial Cell Culture Media: Uncovering the Impact of Trace Metal Impurities on CHO Cell Culture Performance and Product Quality, Presented by Debora L., Gilead Sciences
B27: Utilizing GORE® Protein Capture Device with Protein A for Rapid Process Development in Cell Line Optimization, Presented by Feng G., W. L. Gore & Associates, Inc.
B28: Demonstration of a Multi-Product Resin Reuse Strategy for the Manufacturing of Clinical and Commercial Antibodies Against COVID-19, Presented by Shawn S., Invivyd, Inc.
B29: A Configurable Modular Plastic Microfluidic Chip for Systematic Parameter Screening and Scalable Liposome Synthesis, Presented by Yeong-Eun Y., Korea Institute of Machinery and Materials
B30: An Innovative and GMP-Friendly Manufacturing Process for Off-the-Shelf Allogeneic CAR-γδ T-Cell Therapy, Presented by Yongchang J,, Legend Biotech
B31: De-Risking Custom Media Supply with Flexible cGMP Liquid and Powder Manufacturing, Presented by Prasanna D., Lonza
B32: Leveraging Bioreactor Off-Gas Process Analytical Technology for Automated N-Stage Inoculation in Ambr250 Microbial Bioprocess, Presented by Ashley J., Merck & Co., Inc.
B33: High Capacity Cation Exchange Membrane Chromatography for mAb Purification in Frontal and Bind Elute Mode, Presented by Vivian P., MilliporeSigma
B34: Activated Carbon Depth Filters for Downstream Impurity Removal, Presented by Hannah V., MilliporeSigma
B35: Virtual Cell for Biomanufacturing. A Novel Way to Boost Antibody Yield by Making Drugs for CHO Cells, Presented by Ling W., National University of Singapore
B36: Affinity Based Purification of Hyaluronidase by Using NaviCapture Ligands, Presented by Josephine H., Navigo Proteins GmbH
B37: Targeted Purification of GLP-1 Therapeutics: NaviCapture Ligands for Semaglutide and Tirzepatide, Presented by Josephine H., Navigo Proteins GmbH
B38: Advancing Lipid Nanoparticle Characterization with Super-Resolution Imaging, Presented by Philipp I., ONI
B39: Low-Loss Aseptic Vial Filling to Maximize Yield in High-Value, Low-Volume Biologics, Presented by John C., Sharp Sterile Manufacturing
B40: Uniform and Stemness-Maintained 3D Spheroids for Next-Generation Cell Therapeutics, Presented by Keunsun A., SPHEBIO Co., Ltd.
B41: Revealing Sub-Visible Contaminants in the Presence of Silicone Oil Using Total Holographic Characterization for Process Analytical Control, Presented by Laura P., Spheryx, Inc.
B42: RedTail Virotherapy (CLD-401): A Systemic Gene Medicine for In Situ IL-15 Superagonist Delivery, Presented by Lina S., StemVac GmbH
B43: Scalable, Automated Benchtop Purification of Antibodies and Fc-Fusion Proteins Using AffinEx™ Protein A SPE Columns, Presented by Heather E., Tecan SP, Inc.
B44: Advancing Bispecific Antibody Downstream Processing with Thermo Scientific™ Polisher ST Membrane Adsorber, Presented by David C., Thermo Fisher Scientific
B45: Simultaneous Aggregate and High-Risk HCP Clearance Using Mixed-Mode Cation Exchange Chromatography in Flow-Through Mode, Presented by Ying C., Thermo Fisher Scientific
B46: High-Throughput Media Screening – Path to Selecting Robust Media and Feed in 12 Weeks, Presented by Michalis M., Thermo Fisher Scientific
B47: Framework for Clarification Strategy Selection in mAb and bsAb Bioprocess Development, Presented by Isaac S., Thermo Fisher Scientific
B48: Rewriting Bioprocessing with Synthetic Affinity Ligands, Presented by Alexandra S., Tozaro
B49: Unified Cuvette-Based Workflow for Characterizing Biologic Formulation Stability, Presented by Curt J., Tulane University
B50: Streamlining Advanced Bioprocess Analytics with Automated LC-MS and Data Integration, Presented by Jurgen S., Waters Corporation
B51: A Teamwork Approach to Sponsor and CDMO Relationships, Presented by Scott B., Advanced Cell & Gene Therapy LLC
B52: Advances in Downstream PAT for Biologics, Vaccines and Gene Vectors, Presented by Daniel S., Wyatt Technology Corporation
B53: BioPilot: Enabling Seamless Integration and Automated Control in Bioprocess Development, Presented by Hiroaki Y., Yokogawa Electric Corporation
B57: Enabling Regulatory Success for Oligonucleotide and RNA Therapeutics Through Strategic CMC Design, Presented by Jyotsna A., Jaipur National University (Virtual Poster)